August 30, 2023 03:26 PM EDT

Cancer drugs in US are ‘not affordable,’ says German study, which suggests setting drug prices by indication

Paul Schloesser

Associate Editor

US policymakers and payers should consider indication-based pricing in a bid to cut down on higher cancer drug costs in the US, according to research …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cancer drugs in US are ‘not affordable,’ says German study, which suggests setting drug prices by indication

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Can­cer drugs in US are ‘not af­ford­able,’ says Ger­man study, which sug­gests set­ting drug prices by in­di­ca­tion

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Cancer drugs in US are ‘not affordable,’ says German study, which suggests setting drug prices by indication

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs